Monitoring Agency Report for the quarter ended 31st March, 2026
PAVNAIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CARE Ratings Limited, the monitoring agency for Pavna Industries' Rs. 210.70 crore preferential issue (equity shares + fully convertible warrants), has submitted its Q4 FY26 report. The company has received Rs. 119.80 crore so far (full equity proceeds of Rs. 89.50 crore plus 25% warrant proceeds of Rs. 30.30 crore), with the balance Rs. 90.90 crore to be received in tranches within 18 months from the January 2025 allotment date. All funds have been deployed as per the disclosed objects: Rs. 81.50 crore for working capital (fully utilized), Rs. 38.30 crore for general corporate purposes, and Rs. 0.28 crore for issue expenses. Strategic acquisitions worth Rs. 78.92 crore remain unexecuted with no targets identified yet. No deviations from offer document objectives were observed. A notable concern flagged by the MA is that the current market price of Rs. 21 per share (post-split, effective Sept 2025) is significantly below the warrant conversion price of Rs. 50.50 per share (post-split equivalent of Rs. 505), raising questions about warrant holder incentive to convert.
The monitoring report is largely positive with clean fund utilization, though the large gap between the market price (Rs. 21) and warrant conversion price (Rs. 50.50) suggests potential dilution risk if the stock rallies, and could weigh on near-term investor sentiment.